Navigation Links
NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinson's Disease and Movement Disorders
Date:6/13/2013

NESS ZIONA, Israel, June 13, 2013 /PRNewswire/ --

NeuroDerm, Ltd. today announced that abstracts reporting results from a phase I study in healthy volunteers, and preliminary results from a phase IIA study in advanced Parkinson's patients, of ND0612, have been selected for presentation  at the 17th International Congress of Parkinson's Disease and Movement Disorders, June 16th-20th in Sydney, Australia.

ND0612 is a proprietary levodopa/carbidopa liquid drug formula under development for continuous administration through a sub-cutaneous (SC) delivery patch that would maintain constant levodopa plasma concentrations.

Details on the Presentations are as follows:

Title: Constant Therapeutic Levodopa Plasma Concentrations Maintained by Continuous Subcutaneous Administration of ND−0612, a Novel Formulation of Levodopa/Carbidopa
Abstract #: 452
Presenter: Peter LeWitt
Poster session: Parkinson's Disease: Clinical Trials
Date and time: Tuesday, June 18th, 12:30pm
Location: Bayside, level, 1 gallery B

Title: ND0612, A Novel Formulation of Levodopa/Carbidopa for Continuous, Subcutaneous Administration, Achieves Steady-State Levodopa Plasma Concentrations in Parkinson's Disease Patients
Abstract #: LBA26
Presenter: Nir Giladi
Poster session: Late Breaking Abstracts
Date and time: Wednesday, June 19th, 12:00pm
Location: Exhibit hall #5

About NeuroDerm

NeuroDerm is an emerging pharmaceutical company that develops therapies for the treatment of CNS diseases. NeuroDerm's technology is based on proprietary reformulations of well-established oral drugs that achieve better efficacy. The company's lead products are ND0612, a novel sub-cutaneous drug formulation for the treatment of Par
'/>"/>

SOURCE NeuroDerm Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of ND0612 for Parkinsons Disease
2. NeuroDerm to Present at the Jefferies 2013 Global Healthcare Conference in New York City
3. NeuroDerm Announces Positive Results of a Phase I Study of ND0612 for the Treatment of Parkinsons Disease
4. NeuroDerm Announces Enrollment in a Phase 1 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
5. Royalty Pharma Announces Offer May Lapse (Be Withdrawn)
6. Anthera Pharmaceuticals Announces Personnel Changes
7. Generex Announces Interview of MD Andersons Dr. Elizabeth Mittendorf, Principal Investigator on Companys AE37 Phase IIb Breast Cancer Efficacy Trial
8. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
9. HeartWare International Announces Intention To Delist From Australian Securities Exchange (ASX)
10. Misonix, Inc. Announces the Grant of Patent by the United States Patent and Trademark Office
11. Mindray Announces Appointment of Three Members to Its Executive Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PRINCETON, N.J. , Dec. 24, 2014 /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today that on ... registered public offering. The Company raised ... offering and intends to use the net proceeds ...
(Date:12/24/2014)... 24, 2014  Diplomat Pharmacy, Inc. (NYSE: ... proud to announce Jennifer Hagerman , Pharm.D., AE-C, ... take office as the president of the Michigan Pharmacists ... will take place Feb. 28, 2015, at the MPA ... the Renaissance Center in Detroit, Michigan ...
(Date:12/24/2014)... SCHOFIELD, Wis. , Dec. 23, 2014 ... and marketer of over-the-counter (OTC) medicinal and healthcare products, ... production of MigraPure® H, a hemp-based, advanced headache relief ... marijuana dispensaries in Colorado , ... . With the MigraPure H Advanced ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... Tolerability and,Additive Antiviral Activity of HCV-796 -, EXTON, ... announced additional data from a Phase 1b study,of ... virus (HCV),polymerase inhibitor at the 42nd Annual Meeting ... Liver (EASL). This meeting is,being held in Barcelona, ...
... Data on Innovative Oncology Compounds at the,American ... PARK, Ill., April 13, 2007 /PRNewswire-FirstCall/ -- ... that target,cancer. Researchers now know that cancer ... new blood vessels to deliver oxygen,and nutrients ...
Cached Medicine Technology:ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 2ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 3ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 4ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 5ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 6Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer 2Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer 3Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer 4
(Date:12/24/2014)... Dallas, TX (PRWEB) December 24, 2014 ... has announced the expansion of his practice and med-spa ... to the practice’s growing list of cosmetic treatments and ... a solution into the skin,” says Dr. Ho. “As ... aging changes such as wrinkles, sun spots, discolorations or ...
(Date:12/24/2014)... Today, Yunx.co.uk, a hot style dress supplier that ... occasion outfits, unveils 65 new bridesmaid dresses ... prices, up to 80% off. , Yunx.co.uk’s dresses are ... designs, gorgeous looks and delicate craftsmanship. These new bridesmaid ... to designing and offering high-quality women’s dresses with fast ...
(Date:12/24/2014)... BambooIndustry.com a famous bamboo flooring company offering bamboo flooring ... announces its multiple layer bamboo panel board collection , ... , Bamboo panel is the product made from 100 ... board features high quality selective bamboo and eco-friendly adhesives ... panel consists of multiple layers of bamboo. , According ...
(Date:12/24/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- Hepatitis C infection ... according to a new study. Treatment advances have made ... but many develop memory and thinking problems, mood swings and ... authors said. It,s believed that long-term infections with other ... may affect the brain. One of the prime suspects has ...
(Date:12/24/2014)... 2014 (HealthDay News) -- Researchers say they have used ... into eggs and sperm. While this had already ... first time that these types of cells -- called ... human stem cells, according to the team at the ... primordial germ cells is one of the earliest events ...
Breaking Medicine News(10 mins):Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Yunx.co.uk Unveils 65 New Bridesmaid Dresses for the UK market 2Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:Hepatitis C Infection Isn't Related to HIV Brain Woes: Study 2
... Program Recognizes Innovative Educators from Stanford University, ... of Maryland and San Diego State University, ... precision,technology leader creating innovative opto-digital solutions in healthcare,life ... 2008,winners in the Olympus Innovation Award Program: Tom ...
... cites the use of fluoroquinones , , MONDAY, March ... to treat children with multidrug-resistant tuberculosis can lead ... including severe pneumonia and meningitis. , That finding ... National Institute for Communicable Diseases in South Africa. ...
... Calif., March 24 Alsius Corporation,(Nasdaq: ... patient temperature,management therapies, has received approval from ... its intravascular temperature management,(IVTM(TM)) systems and catheters ... warming therapy via a computer-controlled temperature,regulation system ...
... currently underway at the Peninsula Medical School in the South ... for the treatment of multiple tumours in the brain. , ... merlin, which in turn cause cancers in a range of ... produce the sheaths that surround and insulate neurons. , Although ...
... at Memorial Sloan-Kettering Cancer Center (MSKCC) has shown that ... can be used to treat Parkinsons disease in mice. ... 23 online edition of the journal Nature Medicine. ... cloning or SCNT has been successfully used to treat ...
... Americans with Medicare who are,considering ... Plan have an important,deadline on the ... from UnitedHealthcare at:, http://media.medialink.com/WebNR.aspx?story=34837 , ... text, graphics and,photos for free and ...
Cached Medicine News:Health News:Olympus Announces 2008 Winners of Olympus Innovation Awards 2Health News:Olympus Announces 2008 Winners of Olympus Innovation Awards 3Health News:Olympus Announces 2008 Winners of Olympus Innovation Awards 4Health News:TB Drug Treatment Can Lead to Severe Pneumonia 2Health News:Alsius Corporation Receives Regulatory Approval in China and Mexico 2Health News:Research to lead to brain tumor therapies 2Health News:Research to lead to brain tumor therapies 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: